The causes of dysphagia in carcinoma of the lung

Por Camidge, D R
Publicado em 2001

The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markers

Por Atherly, A J, Camidge, D R
Publicado em 2012

Factors affecting the mesothelioma detection rate within national and international epidemiological studies: insights from Scottish linked cancer registry-mortality data

Por Camidge, D R, Stockton, D L, Bain, M
Publicado em 2006

The impact of socioeconomic status on access to cancer clinical trials

Por Sharrocks, K, Spicer, J, Camidge, D R, Papa, S
Publicado no Br J Cancer (2014)

The epidemiology of self-poisoning in the UK

Por Camidge, D R, Wood, R J, Bateman, D N
Publicado em 2003

Economic evaluation of fulvestrant as an extra step in the treatment sequence for ER-positive advanced breast cancer

Por Cameron, D A, Camidge, D R, Oyee, J, Hirsch, M
Publicado em 2008

Hospital admissions and deaths relating to deliberate self-harm and accidents within 5 years of a cancer diagnosis: a national study in Scotland, UK

Por Camidge, D R, Stockton, D L, Frame, S, Wood, R, Bain, M, Bateman, D N
Publicado em 2007

A phase I, open-label dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced...

Por Doebele, R. C., Conkling, P., Traynor, A. M., Otterson, G. A., Zhao, Y., Wind, S., Stopfer, P., Kaiser, R., Camidge, D. R.
Publicado em 2012

Assessing proliferation, cell-cycle arrest and apoptotic end points in human buccal punch biopsies for use as pharmacodynamic biomarkers in drug development

Por Camidge, D R, Pemberton, M N, Growcott, J W, Johnstone, D, Laud, P J, Foster, J R, Randall, K J, Hughes, A M
Publicado em 2005

A phase I study of sunitinib combined with modified FOLFOX6 in patients with advanced solid tumors

Por Leong, S., Eckhardt, S. G., Chan, E., Messersmith, W. A., Spratlin, J., Camidge, D. R., Diab, S., Khosravan, R., Lin, X., Maneval, E. Chow, Lockhart, A. C.
Publicado em 2012

Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumo...

Por Kris, M. G., Camidge, D. R., Giaccone, G., Hida, T., Li, B. T., O'Connell, J., Taylor, I., Zhang, H., Arcila, M. E., Goldberg, Z., Jänne, P. A.
Publicado no Ann Oncol (2015)

Plucked human hair as a tissue in which to assess pharmacodynamic end points during drug development studies

Por Camidge, D R, Randall, K R, Foster, J R, Sadler, C J, Wright, J A, Soames, A R, Laud, P J, Smith, P D, Hughes, A M
Publicado em 2005

A phase I dose-escalation and pharmacokinetic study of sunitinib in combination with pemetrexed in patients with advanced solid malignancies, with an expanded cohort in non-small c...

Por Chow, L. Q. M., Blais, N., Jonker, D. J., Laurie, S. A., Diab, S. G., Canil, C., McWilliam, M., Thall, A., Ruiz-Garcia, A., Zhang, K., Tye, L., Chao, R. C., Camidge, D. R.
Publicado em 2011

Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma

Por Krug, A K, Enderle, D, Karlovich, C, Priewasser, T, Bentink, S, Spiel, A, Brinkmann, K, Emenegger, J, Grimm, D G, Castellanos-Rizaldos, E, Goldman, J W, Sequist, L V, Soria, J -C, Camidge, D R, Gadgeel, S M, Wakelee, H A, Raponi, M, Noerholm, M, Skog, J
Publicado no Ann Oncol (2018)